Business Context and Reporting Period
Company: Capricor Therapeutics, Inc. (CAPR)
Filing Type: Form 8-K (Current Report)
Report Date: March 10, 2022
Reporting Period: Fourth Quarter and Full Year ended December 31, 2021
This filing serves as a notification that the Company issued a press release announcing its financial results for the specified period. The detailed financial data is contained in Exhibit 99.1 (Press Release) and is not directly embedded in the text of this Form 8-K.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached press release (Exhibit 99.1) but are not disclosed within the body of this 8-K filing.
Material Changes
No specific material changes or comparative financial data versus prior periods are detailed in this document. The filing solely references the announcement of results for the quarter and full year ended December 31, 2021.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that the press release includes a "Corporate Update" alongside financial results, though the specific content of this update is not provided in the text.
Legal Disclaimer: The information furnished under Item 2.02 and Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for Q4 and Full Year 2021.
- Verify the "Corporate Update" details regarding clinical trial progress or strategic initiatives mentioned in the press release.
- Confirm the Company's cash runway and burn rate as disclosed in the full financial statements referenced by the press release.
- Check for any forward-looking statements or guidance updates included in the attached press release.